← Back to Search

TMS for Speech

N/A
Waitlist Available
Led By Carrie Niziolek, PhD
Research Sponsored by University of Wisconsin, Madison
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
English-speaking adults
No history of stroke or neurological conditions
Must not have
Family history of epilepsy
Any neurological disorders other than the disorder of interest
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 1 hour
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to study how the brain processes and controls speech in healthy individuals. By understanding this, researchers hope to identify how people perceive their own speech errors and learn new speech sounds. This information may

Who is the study for?
This trial is for healthy individuals interested in how the brain controls speech. Participants should be available for 4 visits, each lasting 2-4 hours. The eligibility criteria are not fully listed here, so potential participants would need to contact the researchers for more details.
What is being tested?
The study is testing the effects of Transcranial Magnetic Stimulation (TMS) on speech processing and control during speaking tasks. It aims to understand how people perceive their own speech errors and learn new sounds.
What are the potential side effects?
While specific side effects are not detailed here, TMS can sometimes cause discomfort at the stimulation site, headache, lightheadedness or seizures in rare cases.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am an adult who speaks English.
Select...
I have never had a stroke or neurological conditions.
Select...
I can hear and speak normally.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My family has a history of epilepsy.
Select...
I do not have any neurological disorders other than the one being studied.
Select...
I am not taking any medications that can cause seizures.
Select...
I have high pressure inside my skull.
Select...
I have a serious heart condition.
Select...
I have a history of seizures.
Select...
I am able to understand and consent to participate in the study.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1 hour
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 hour for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Acoustic vowel space measures: AVS (acoustic vowel spacing)/VSA (vowel space area)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Healthy Adult SpeakersExperimental Treatment2 Interventions
healthy adult participants across the lifespan in three groups:18-35, 36-55, and 56+
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Speaking Tasks
2021
N/A
~20
TMS
2021
Completed Phase 2
~2170

Find a Location

Who is running the clinical trial?

University of Wisconsin, MadisonLead Sponsor
1,230 Previous Clinical Trials
3,199,810 Total Patients Enrolled
3 Trials studying Speech
149 Patients Enrolled for Speech
National Institute on Deafness and Other Communication Disorders (NIDCD)NIH
353 Previous Clinical Trials
181,462 Total Patients Enrolled
15 Trials studying Speech
2,036 Patients Enrolled for Speech
Carrie Niziolek, PhDPrincipal InvestigatorUniversity of Wisconsin, Madison
3 Previous Clinical Trials
149 Total Patients Enrolled
3 Trials studying Speech
149 Patients Enrolled for Speech
~10 spots leftby Jul 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top